I'm excited to launch this new Twitter account where updates and opportunities linked to my #perinatal anxiety #research will be shared. Please follow and share with anyone interested in #maternal #postnatal #Mentalhealth Here's a little introductory thread to explain more...1/9

Online survey investigating postnatal anxiety launching 1st May 2021! I'm keen to reach traditionally under-represented groups of mothers in the UK - can you or your organisation help? Drop me a message through Twitter or email (details in image) for more information. Thanks!

There are "plenty of things" that happen in the House of Commons "that I wish were banned, however Stella Creasy's baby isn't one of them," says Jess Phillips, adding all employers should be "making small adjustments" to help mothers feel welcome at work. trib.al/4Q2EIx9

So thrilled that Deborah James has got this recognition. Words fail me when it comes to the situation she is in, but my goodness… what a legacy!! Over £3.5 million for charity and rising!! What an absolute star!! 🌟🥰

My story has just been published on the Roy Castle website. I hope that this will help others who find themselves in the same situation… so please do share it. roycastle.org/ginis-lung-can… #lungcancer #fightingcancer #mumswithcancer

Does someone in your family work for the #police? The OU is doing research into the wellbeing & support needs of police families. Get more information and take part by clicking here: openss.qualtrics.com/jfe/form/SV_1Z…

The fabulous Son of Cormack at Lakefest. Definitely worth a listen!! Andy and I also feature in the interview. Fame at last!?! 😂

Truly humbling session. Anyone with lungs can get lung cancer

Evidence for the effectiveness of online cognitive behaviour therapy in supporting perinatal mental health. Please share: authors.elsevier.com/c/1hDnFbXYirCa3

This is big news for UK. Mobocertinib is the only reimbursed ex20 inhibitor we have (post platinum) and its withdrawal will leave a big void until other agents get licensed and reimbursed BTOG

Dark day for #EGFR #exon20 pts when discussions betw. FDA Oncology & Takeda Oncology led to a decision re #mobocertinib's withdrawal (timing unclear). No words! We've worked w/mobo since early 2017 & need it to be available as one of our 2 anchor drugs. 844-662-8532 (Takeda info)

Lung cancer: Why non-smokers don't respond to treatments via ⁦Medical News Today⁩ “All you need to be at risk for lung cancer is to have lungs,” Singhi told Medical News Today ⁦⁦ medicalnewstoday.com/articles/why-m…

#ESMO24 Sanjay Popat presents an interim OS update for MARIPOSA-2 (amivantamab + chemotherapy vs chemotherapy in #EGFR mutant NSCLC post osimertinib). OS trend favors adding amivantamab (HR 0.73), not yet statistically significant. 18m OS rate 50% vs 40%. #ESMOAmbassadors

Prof Charles Swanton finds use of ctDNA in operable #lungcancer determines relapse at #ESMO24. Positive pre-operative ctDNA predicts odds of relapse. Should ctDNA use be standard in all operable cases? Will this inform treatment in future esp those w pre-operative ctDNA?

Our Research Trustee, Gini Harrison, talking about the real challenges of managing skin issues caused by #EGFR treatments & how this affects sticking with treatment. Important stuff for improving life with #lungcancer. #ESMO24

Genuine goosebumps. I wish she would run. I have cast my vote… let’s hope people listen to her. 🤞🏻

Osimertinib BEATEN!! MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, p<0.005, 3yr 60% vs 51%) and landmark 3-yr icPFS improvement (36% vs 18%)—first combo to show OS superiority over SoC, extending OS beyond 3 years in 1L EGFRm NSCLC. #ESMOAmbassadors #ELCC25 ESMO - Eur. Oncology

Osimertinib after definitive chemoradiotherapy is a "new standard of care" in unresectable, stage III, EGFR-mutant NSCLC, reported Suresh S. Ramalingam, MD, FASCO of Winship Cancer Institute of Emory University in an updated analysis of the LAURA study presented at #ELCC25. #ELCC2025 #lcsm